The Russian offices of Swiss pharmaceutical giant Novartis have been searched by police, a company spokeswoman confirmed to the Reuters news agency.
This content was published on
1 minute
swissinfo.ch and agencies
It was one of four pharmaceutical companies in Moscow to be searched, according to the Russian business daily Vedomosti.
A police source had told the newspaper the searches were part of an investigation into an alleged carve-up of the market for supplying the state healthcare system with essential drugs.
An investigation into the government’s system of subsidised drugs for low income citizens showed the bulk of state supply contracts worth over $2 billion (SFr1.69 billion) went to six distribution firms in 2006-2008.
The Novartis spokeswoman in Moscow said the company was cooperating with police but she declined to comment on the cause of the investigation.
International pharmaceutical firms currently control about 80 per cent of the Russian drugs market, which is seen as a fast-growing market to offset slowing sales in the West.
Novartis plans to invest $500 million in Russia over the next five years and build a plant in St Petersburg to strengthen its position in the market, which is expected to exceed $60 billion by 2020.
You can find an overview of ongoing debates with our journalists here. Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.
Read more
More
Swiss firms muscle into Slovenian markets
This content was published on
The country joined the European Union in 2004 and receives financial contributions from Switzerland as part of efforts to reduce social and economic disparities. Well-known brand names such as Landis+Gyr, Sibir, Geberit and Eternit as well as the pharmaceutical giant Novartis and the engineering company ABB are among the Swiss firms that have opened offices…
This content was published on
Swiss giants Novartis and Roche reported relatively healthy balance sheets for 2010, but have warned of tough times ahead. The global recession has forced the United States, Japan and European states to demand more for less from drugs firms. Roche estimates that the European and US healthcare measures will cost the group a combined SFr1…
This content was published on
Paul Herrling, the Swiss head of corporate research at pharmaceutical concern Novartis, was among 21 people approved this week to join a WHO expert group evaluating funding for projects into neglected tropical diseases – those illnesses affecting the poorest populations. He is the only expert in the group who is also an executive in the…
This content was published on
War and peace, work and leisure, rich and poor, expected and unexpected: regular contacts between Switzerland and Russia go back to the 18th century.
You can find an overview of ongoing debates with our journalists here. Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.